PSA markers in prostate cancer detection

Matthew B Gretzer, Alan W. Partin

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

The PSA revolution that has occurred over the previous 2 decades has positively impacted the detection and treatment of men with prostate cancer. Although methods to improve specificity have shown promise (eg, PSAD, age-specific PSA, and PSA velocity), meaningful interpretation has yet to be uniformly accepted within clinical practice. The identification of other molecular forms of PSA within serum has led to a new era in PSA markers. Initial application employing %fPSA has provided improved discrimination between benign and malignant prostatic disease; however, questions remain regarding the ultimate threshold value. The discovery of various free forms of PSA-such as proPSA, BPSA, and iPSA-also have introduced the potential for improved specificity in detection. Although early results are encouraging, further evaluation is anticipated. The development of improved methods to detect and measure cPSA has demonstrated provocative results, and exhibits the potential to replace PSA as a standard diagnostic test in cancer screening.

Original languageEnglish (US)
Pages (from-to)677-686
Number of pages10
JournalUrologic Clinics of North America
Volume30
Issue number4
DOIs
StatePublished - Nov 2003
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Prostatic Diseases
Early Detection of Cancer
Routine Diagnostic Tests
Serum
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

PSA markers in prostate cancer detection. / Gretzer, Matthew B; Partin, Alan W.

In: Urologic Clinics of North America, Vol. 30, No. 4, 11.2003, p. 677-686.

Research output: Contribution to journalArticle

Gretzer, Matthew B ; Partin, Alan W. / PSA markers in prostate cancer detection. In: Urologic Clinics of North America. 2003 ; Vol. 30, No. 4. pp. 677-686.
@article{9ee1dca75ed84d13a00855a3d6c114bd,
title = "PSA markers in prostate cancer detection",
abstract = "The PSA revolution that has occurred over the previous 2 decades has positively impacted the detection and treatment of men with prostate cancer. Although methods to improve specificity have shown promise (eg, PSAD, age-specific PSA, and PSA velocity), meaningful interpretation has yet to be uniformly accepted within clinical practice. The identification of other molecular forms of PSA within serum has led to a new era in PSA markers. Initial application employing {\%}fPSA has provided improved discrimination between benign and malignant prostatic disease; however, questions remain regarding the ultimate threshold value. The discovery of various free forms of PSA-such as proPSA, BPSA, and iPSA-also have introduced the potential for improved specificity in detection. Although early results are encouraging, further evaluation is anticipated. The development of improved methods to detect and measure cPSA has demonstrated provocative results, and exhibits the potential to replace PSA as a standard diagnostic test in cancer screening.",
author = "Gretzer, {Matthew B} and Partin, {Alan W.}",
year = "2003",
month = "11",
doi = "10.1016/S0094-0143(03)00057-0",
language = "English (US)",
volume = "30",
pages = "677--686",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - PSA markers in prostate cancer detection

AU - Gretzer, Matthew B

AU - Partin, Alan W.

PY - 2003/11

Y1 - 2003/11

N2 - The PSA revolution that has occurred over the previous 2 decades has positively impacted the detection and treatment of men with prostate cancer. Although methods to improve specificity have shown promise (eg, PSAD, age-specific PSA, and PSA velocity), meaningful interpretation has yet to be uniformly accepted within clinical practice. The identification of other molecular forms of PSA within serum has led to a new era in PSA markers. Initial application employing %fPSA has provided improved discrimination between benign and malignant prostatic disease; however, questions remain regarding the ultimate threshold value. The discovery of various free forms of PSA-such as proPSA, BPSA, and iPSA-also have introduced the potential for improved specificity in detection. Although early results are encouraging, further evaluation is anticipated. The development of improved methods to detect and measure cPSA has demonstrated provocative results, and exhibits the potential to replace PSA as a standard diagnostic test in cancer screening.

AB - The PSA revolution that has occurred over the previous 2 decades has positively impacted the detection and treatment of men with prostate cancer. Although methods to improve specificity have shown promise (eg, PSAD, age-specific PSA, and PSA velocity), meaningful interpretation has yet to be uniformly accepted within clinical practice. The identification of other molecular forms of PSA within serum has led to a new era in PSA markers. Initial application employing %fPSA has provided improved discrimination between benign and malignant prostatic disease; however, questions remain regarding the ultimate threshold value. The discovery of various free forms of PSA-such as proPSA, BPSA, and iPSA-also have introduced the potential for improved specificity in detection. Although early results are encouraging, further evaluation is anticipated. The development of improved methods to detect and measure cPSA has demonstrated provocative results, and exhibits the potential to replace PSA as a standard diagnostic test in cancer screening.

UR - http://www.scopus.com/inward/record.url?scp=0344011553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344011553&partnerID=8YFLogxK

U2 - 10.1016/S0094-0143(03)00057-0

DO - 10.1016/S0094-0143(03)00057-0

M3 - Article

C2 - 14680307

AN - SCOPUS:0344011553

VL - 30

SP - 677

EP - 686

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 4

ER -